Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/17/2017 04/18/2017 04/19/2017 04/20/2017 04/21/2017 Date
90.7(c) 90.95(c) 90.17(c) 90.23(c) 88.47(c) Last
559 294 940 783 868 878 825 515 1 449 161 Volume
+0.88% +0.28% -0.86% +0.07% -1.95% Change
More quotes
Financials ($)
Sales 2017 1 269 M
EBIT 2017 -156 M
Net income 2017 -167 M
Debt 2017 34,0 M
Yield 2017 -
Sales 2018 1 472 M
EBIT 2018 -37,3 M
Net income 2018 -62,5 M
Debt 2018 37,6 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 12,1x
EV / Sales2018 10,4x
Capitalization 15 293 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the biopharmaceutical development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded on March 21, 1997 and... 
Sector
Pharmaceuticals
Calendar
08/02Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
04/21 BIOMARIN PHARMACEUTICAL : Receives Positive CHMP Opinion in Europe for Brineura&..
04/21 BIOMARIN PHARMACEUTICAL : Receives Positive CHMP Opinion in Europe for Brineura(..
04/20 BIOMARIN TO HOST FIRST QUARTER 2017 : 30pm ET
04/20 BIOMARIN PHARMACEUTICAL : Announces Kuvan® sapropterin dihydrochloride Patent Ch..
04/13 BIOMARIN PHARMACEUTICAL : Findings on Macular Degeneration Discussed by Investig..
04/13 BIOMARIN PHARMACEUTICAL : Findings from BioMarin Pharmaceutical Inc. Update Unde..
04/13 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) Files An 8-K Entry into a Material ..
04/13 BIOMARIN PHARMACEUTICAL INC : Entry into a Material Definitive Agreement, Other ..
04/13 BIOMARIN PHARMACEUTICAL : Announces Kuvan® (sapropterin dihydrochloride) Patent ..
04/06 BIOMARIN PHARMACEUTICAL : New Adeno-Associated Virus Study Findings Have Been Re..
More news
Sector news : Biopharmaceuticals
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
04/19DJFARON PHARMACEUTICALS OY : Appoints Two Non-Executive Directors
More sector news : Biopharmaceuticals
Latest Tweets
04/21$BMRN: BioMarin Pharm confirms that the CHMP has adopted a positive opinion f..
1
04/21EMA hands down a number of recommendations  
04/21BioMarin To Host First Quarter 2017 Financial Results Conference Call And Web.. 
04/21on Cramer tonight ... $PFPT $BMRN 
04/20BioMarin to Host First Quarter 2017 Financial Results Conference Call and Web.. 
More tweets
Qtime:67
News from SeekingAlpha
04/21 EMA hands down a number of recommendations
04/17 Roche's emicizumab shows treatment benefit in second late-stage hemophilia A ..
04/13 BioMarin settles Kuvan patent dispute with Par Pharma, generic version allowe..
04/07 Biomarin's Rare Disease Approval And Probiodrug's Alzheimer's Play
03/30 Premarket analyst action - healthcare
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 111 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Henry J. Fuchs Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Elaine J. Heron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..6.80%15 293
BIOGEN INC4.44%58 942
CSL LIMITED27.90%43 947
ALEXION PHARMACEUTICAL..-4.52%26 302
GRIFOLS SA25.00%16 002
CHONGQING ZHIFEI BIOLO..--.--%4 539
More Results